Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...
Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback